Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction

Autores
Bessone, Fernando; Roma, Marcelo Gabriel
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Ursodeoxycholic acid (UDCA) is the first choice medication for most cholestatic hepatopathies, due to its capability to counteract inflammation and bile-acid-induced liver damage, two common features in cholestasis. However, UDCA is usually contraindicated in obstructive cholestasis, due to the alleged risk of biliary integrity disruption due to its choleretic effect. We report on an 83-year-old man with an unsuspected malignant biliary obstruction who received moderate doses of UDCA (8-12 mg/kg/day) for 5 weeks, because the preliminary evidence suggested he had chemotherapy-induced cholestasis. Liver integrity was extensively protected by UDCA, as indicated by a marked decrease in serum liver enzymes, despite a steady increase in the levels of bilirubin and serum bile acids due to the obstructive process. In conclusion, this report shows, for the first time in humans, that moderate UDCA doses can reduce liver injury associated with complete biliary obstruction. This may contribute to a better understanding of the risk-benefit ratio of the use of UDCA in obstructive cholangiopathies.
Fil: Bessone, Fernando. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Roma, Marcelo Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Fisiología Experimental. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental; Argentina
Materia
Biliary Tract
Liver Function Test
Malignant Biliary Obstruction
Obstructive Cholestasis
Ursodeoxycholic Acid (Udca)
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/53059
Acceder
id CONICETDig_6fdb50c5fd2fa0a74ac4b7e1030e7703
oai_identifier_str oai:ri.conicet.gov.ar:11336/53059
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstructionBessone, FernandoRoma, Marcelo GabrielBiliary TractLiver Function TestMalignant Biliary ObstructionObstructive CholestasisUrsodeoxycholic Acid (Udca)https://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Ursodeoxycholic acid (UDCA) is the first choice medication for most cholestatic hepatopathies, due to its capability to counteract inflammation and bile-acid-induced liver damage, two common features in cholestasis. However, UDCA is usually contraindicated in obstructive cholestasis, due to the alleged risk of biliary integrity disruption due to its choleretic effect. We report on an 83-year-old man with an unsuspected malignant biliary obstruction who received moderate doses of UDCA (8-12 mg/kg/day) for 5 weeks, because the preliminary evidence suggested he had chemotherapy-induced cholestasis. Liver integrity was extensively protected by UDCA, as indicated by a marked decrease in serum liver enzymes, despite a steady increase in the levels of bilirubin and serum bile acids due to the obstructive process. In conclusion, this report shows, for the first time in humans, that moderate UDCA doses can reduce liver injury associated with complete biliary obstruction. This may contribute to a better understanding of the risk-benefit ratio of the use of UDCA in obstructive cholangiopathies.Fil: Bessone, Fernando. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; ArgentinaFil: Roma, Marcelo Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Fisiología Experimental. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental; ArgentinaMexican Association of Hepatology2016-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/53059Bessone, Fernando; Roma, Marcelo Gabriel; Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction; Mexican Association of Hepatology; Annals of Hepatology; 15; 3; 5-2016; 442-4471665-2681CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.5604/16652681.1198824info:eu-repo/semantics/altIdentifier/url/https://annalsofhepatology.publisherspanel.com/resources/html/article/details?id=127642info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:05:22Zoai:ri.conicet.gov.ar:11336/53059instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:05:23.121CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction
title Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction
spellingShingle Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction
Bessone, Fernando
Biliary Tract
Liver Function Test
Malignant Biliary Obstruction
Obstructive Cholestasis
Ursodeoxycholic Acid (Udca)
title_short Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction
title_full Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction
title_fullStr Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction
title_full_unstemmed Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction
title_sort Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction
dc.creator.none.fl_str_mv Bessone, Fernando
Roma, Marcelo Gabriel
author Bessone, Fernando
author_facet Bessone, Fernando
Roma, Marcelo Gabriel
author_role author
author2 Roma, Marcelo Gabriel
author2_role author
dc.subject.none.fl_str_mv Biliary Tract
Liver Function Test
Malignant Biliary Obstruction
Obstructive Cholestasis
Ursodeoxycholic Acid (Udca)
topic Biliary Tract
Liver Function Test
Malignant Biliary Obstruction
Obstructive Cholestasis
Ursodeoxycholic Acid (Udca)
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Ursodeoxycholic acid (UDCA) is the first choice medication for most cholestatic hepatopathies, due to its capability to counteract inflammation and bile-acid-induced liver damage, two common features in cholestasis. However, UDCA is usually contraindicated in obstructive cholestasis, due to the alleged risk of biliary integrity disruption due to its choleretic effect. We report on an 83-year-old man with an unsuspected malignant biliary obstruction who received moderate doses of UDCA (8-12 mg/kg/day) for 5 weeks, because the preliminary evidence suggested he had chemotherapy-induced cholestasis. Liver integrity was extensively protected by UDCA, as indicated by a marked decrease in serum liver enzymes, despite a steady increase in the levels of bilirubin and serum bile acids due to the obstructive process. In conclusion, this report shows, for the first time in humans, that moderate UDCA doses can reduce liver injury associated with complete biliary obstruction. This may contribute to a better understanding of the risk-benefit ratio of the use of UDCA in obstructive cholangiopathies.
Fil: Bessone, Fernando. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Roma, Marcelo Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Fisiología Experimental. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental; Argentina
description Ursodeoxycholic acid (UDCA) is the first choice medication for most cholestatic hepatopathies, due to its capability to counteract inflammation and bile-acid-induced liver damage, two common features in cholestasis. However, UDCA is usually contraindicated in obstructive cholestasis, due to the alleged risk of biliary integrity disruption due to its choleretic effect. We report on an 83-year-old man with an unsuspected malignant biliary obstruction who received moderate doses of UDCA (8-12 mg/kg/day) for 5 weeks, because the preliminary evidence suggested he had chemotherapy-induced cholestasis. Liver integrity was extensively protected by UDCA, as indicated by a marked decrease in serum liver enzymes, despite a steady increase in the levels of bilirubin and serum bile acids due to the obstructive process. In conclusion, this report shows, for the first time in humans, that moderate UDCA doses can reduce liver injury associated with complete biliary obstruction. This may contribute to a better understanding of the risk-benefit ratio of the use of UDCA in obstructive cholangiopathies.
publishDate 2016
dc.date.none.fl_str_mv 2016-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/53059
Bessone, Fernando; Roma, Marcelo Gabriel; Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction; Mexican Association of Hepatology; Annals of Hepatology; 15; 3; 5-2016; 442-447
1665-2681
CONICET Digital
CONICET
url http://hdl.handle.net/11336/53059
identifier_str_mv Bessone, Fernando; Roma, Marcelo Gabriel; Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant Biliary obstruction; Mexican Association of Hepatology; Annals of Hepatology; 15; 3; 5-2016; 442-447
1665-2681
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.5604/16652681.1198824
info:eu-repo/semantics/altIdentifier/url/https://annalsofhepatology.publisherspanel.com/resources/html/article/details?id=127642
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Mexican Association of Hepatology
publisher.none.fl_str_mv Mexican Association of Hepatology
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613889130496000
score 13.070432

Publicaciones similares